Overview of depression and its management in children and adolescents

Formulary

Volumn 44, Issue 6, 2009, Pages 172-180

  Lenz, Kimberly ^a,b   Coderre, Karen ^a,b   Watanabe, Mark D ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; OMEGA 3 FATTY ACID; PAROXETINE; PLACEBO; QUETIAPINE; REBOXETINE; RILUZOLE; SERTRALINE; VENLAFAXINE;

ADJUVANT THERAPY; ADOLESCENT; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR CHANGE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; CHILD; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FAMILY HISTORY; FAMILY THERAPY; HUMAN; HYPERICUM PERFORATUM; LEARNING DISORDER; MAINTENANCE THERAPY; MAJOR DEPRESSION; MENTAL STRESS; OBSESSIVE COMPULSIVE DISORDER; PRACTICE GUIDELINE; PSYCHOEDUCATION; PULSE RATE; REVIEW; SIDE EFFECT; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 77951953807     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Son SE, Kirchner JT. Depression in children and adolescents. Am Fam Physician. 2000;62:2297-2308, 2311-2312.
2. Lewinsohn PM, Rohde P, Seeley JR. Major depressive disorder in older adolescents: Prevalence, risk factors, and social implications. Clin Psychol Rev. 1998;18:765-794.
3. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: A review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry. 1996;35:1427-1439. (Pubitemid 26360928)
4. An update on depression in children and adolescents. J Clin Psychiatry. 2008;69:1818-1828.
5. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46:1503-1526.
6. Calles JL Jr. Depression in children and adolescents. Prim Care. 2007;34:243-258.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
8. Hughes CW, Emslie GJ, Crimson ML, et al; Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Texas Children's Medication Algorithm Project: Update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:667-686.
9. Cheung AH, Zuckerbrot RA, Jensen PS, Ghalib K, Laraque D, Stein RE; GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management. Pediatrics. 2007;120:e1313-e1326.
10. [erratum in Pediatrics. 2008;121:227]
11. Emslie GJ, Hughes CW, Crimson ML, et al; Texas Children's Medication Algorithm Project (CMAP). A feasibility study of the childhood depression medication algorithm: The Texas Children's Medication Algorithm Project (CMAP). J Am Acad Child Adolesc Psychiatry. 2004;43:519-527.
12. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry. 2005;46:735-754.
13. Lloyd A, Horan W, Bogaro SR, Stokes JM, Pogge DL, Harvey PD. Predictors of medication compliance after hospital discharge in adolescent psychiatric patients. J Child Adolesc Psychopharmacol. 1998;8:133-141.
14. Watanabe N, Hunot V, Omori IM, Churchill R, Furukawa TA. Psychotherapy for depression among children and adolescents: A systematic review. Acta Psychiatr Scand. 2007;116:84-95.
15. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: A meta-analysis. Psychol Bull. 2006;132:132-149.
16. Curry JF. Specific psychotherapies for childhood and adolescent depression. Biol Psychiatry. 2001;49:1091-1100.
17. Vitiello B, Rohde P, Silva S, et al; TADS Team. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006;45:1419-1426. (Pubitemid 44900915)
18. Van der Watt G, Laugharne J, Janca A. Complementary and alternative medicine in the treatment of anxiety and depression. Curr Opin Psychiatry. 2008;21:37-42.
19. Jorm AF, Allen NB, O'Donnell CP, Parslow RA, Purcell R, Morgan AJ. Effectiveness of complementary and self-help treatments for depression in children and adolescents. Med J Aust. 2006;185:368-372.
20. Cheung AH, Emslie GJ, Mayes TL. The use of antidepressants to treat depression in children and adolescents. CMAJ. 2006;174:193-200.
21. March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents With Depression Study (TADS): Long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007;64:1132-1144.
22. [erratum in Arch Gen Psychiatry. 2008;65:101]
23. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA. 2008;299:901-913.
24. Goodyer IM, Dubicka B, Wilkinson P, et al. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technol Assess. 2008;12:iii-iv, ix-60.
25. Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38:513-516.
26. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev. 2002;(2): CD002317.
27. Moreland CS, Bonin L. Psychopharmacological treatment for adolescent depression. Up To Date database. www.utdol.com/utd/index.do. Accessed May 28, 2009.
28. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-bind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031-1037.
29. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1205-1215.
30. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: A randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry. May 2009 [Epub ahead of print].
31. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry. 2004;161:1079-1083.
32. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet. 2004;363:1341-1345.
33. Micromedex Healthcare Series. Thomson Healthcare. http://www.thomsonhc. com. Accessed May 12, 2009.
34. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebocontrolled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry. 2004;161:1079-1083.
35. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001;40:762-772.
36. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65:432-441.
37. Suppes T, Dermehy EB, Hirschfeld RM, et al. Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: Update to the algorithms for treatment of bipolar disorder. J Clin Psychiatry. 2005;66:870-886.
38. Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry. 2006;45:298-304.
39. Chang KD. The use of atypical antipsychotics in pediatric bipolar disorder. J Clin Psychiatry. 2008;69(suppl 4):4-8.
40. Pathak S, Johns ES, Kowatch RA. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: A case series. J Child Adolesc Psychopharmacol 2005;15;696-702.
41. DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry. 2007;68:789-795.
42. Papakostas GI, Nelson JC, Kasper S, Moller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2008;18:122-127.
43. Ratner S, Laor N, Bronstein Y, Weizman A, Toren P. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:428-433. (Pubitemid 40559690)
44. Toren P, Ratner S, Weizman A, Lask M, Ben-Amitay G, Laor N. Reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder: a long-term follow-up open study. J Child Adolesc Psychopharmacol. 2007;17:803-811.
45. Reboxetine treatment in depressed children and adolescents an 8-week, open study. Clinicaltrials.gov. http://clinicaltrials.gov/ct2/show/NCT00426946? term=reboxetine&rank=6. Accessed May 22, 2009.
46. Zarate CA Jr, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161:171-174.
47. Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry. 2007;61:822-825.
48. Zarate CA Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57:430-432.
49. Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2007;17:761-767.
50. Double-blind placebo-controlled trial of riluzole in pediatric bipolar disorder. Clinicaltrials.gov. http://clinicaltrials.gov/ct2/show/NCT00805493? term=riluzole&rank=13. Accessed May 22, 2009.
51. Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother. 2008;42:1822-1831.
52. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68:1723-1732.